Funded Biotechnology Startups in La Jolla
La Jolla's biotechnology cluster has produced 17 rounds spanning September 2020 through August 2025, with disclosed amounts ranging from $900K (Dare Biosci…
La Jolla's biotechnology cluster has produced 17 rounds spanning September 2020 through August 2025, with disclosed amounts ranging from $900K (Dare Bioscience) to $350M (Janux Therapeutics, December 2024). Nine of the 17 rounds carry a Series Unknown or Venture – Series Unknown classification; among rounds with explicit stage labels, Series B is most common, with Genome Insight, Singlera Genomics, PetDx, and Zerigo Health each closing at that tier.
2023 stands out as the most active year by count, accounting for six rounds between April and November — Boundless Bio ($100M Series C), Rampart Bioscience ($85M Series A), Ambrx ($75M), Epic Sciences ($24M Series G), Genome Insight ($23M Series B), and Tentarix Biotherapeutics (undisclosed). The 2024–2025 period brought three rounds of $150M or more: Janux Therapeutics ($350M, December 2024), Kura Oncology ($150M, January 2024), and Inhibrx ($150M, January 2025).
Most recent rounds
17 shownRelated listings
Frequently asked
What are the largest recent rounds among La Jolla biotech companies in this group?
Janux Therapeutics raised $350M in December 2024, the largest disclosed round in the cohort. Inhibrx and Kura Oncology each raised $150M — in January 2025 and January 2024, respectively. Boundless Bio's $100M Series C (May 2023) and Rampart Bioscience's $85M Series A (October 2023) rank next by disclosed size.
How many of these companies raised money in 2024 or 2025?
Six rounds fall within January 2024 through August 2025: Kura Oncology ($150M), INmuneBIO ($13M), Janux Therapeutics ($350M), Inhibrx ($150M), CalciMedica ($10M), and Equillium ($30M). The combined disclosed total from those six rounds is $703M.
What does the funding stage distribution look like across these 17 rounds?
Nine rounds are classified as Series Unknown or Venture – Series Unknown. Among explicitly staged rounds, Series B appears four times (Genome Insight, Singlera Genomics, PetDx, Zerigo Health), with one each of Series A (Rampart Bioscience), Series C (Boundless Bio), and Series G (Epic Sciences).
Which year saw the most La Jolla biotech funding rounds in this dataset?
2023 accounts for six of the 17 rounds — more than any other calendar year shown. That cohort includes Boundless Bio ($100M Series C), Rampart Bioscience ($85M Series A), Ambrx ($75M), Epic Sciences ($24M Series G), Genome Insight ($23M Series B), and Tentarix Biotherapeutics (undisclosed).
Which company reached the most advanced labeled funding stage?
Epic Sciences closed a Series G round in April 2023 at $24M, the highest explicitly labeled stage in this cohort.
What is the range of disclosed deal sizes in this La Jolla biotech group?
Disclosed rounds range from $900K (Dare Bioscience, September 2020) to $350M (Janux Therapeutics, December 2024). One round — Tentarix Biotherapeutics (August 2023) — was undisclosed.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.